Preparation of dry powder dispersions for non‐viral gene delivery by freeze‐drying and spray‐drying
- 30 April 2002
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 4 (4) , 428-437
- https://doi.org/10.1002/jgm.282
Abstract
Dry powder dispersion devices offer potential for delivering therapeutic macromolecules to the pulmonary epithelia. Previously, freeze-drying (lyophilisation) has been the accepted method for preparing dried formulations of proteins and non-viral gene vectors despite the respirability of such powders being inadequate without further processing. In this study we compare the utility of freeze-drying and spray-drying, a one-step process for producing dry and respirable powders, as methods for preparing non-viral respiratory gene delivery systems. Lipid:polycation:pDNA (LPD) vectors comprising 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), protamine sulphate and pEGFP-N1 in 3% lactose solution were either snap-frozen and lyophilised or spray-dried. Lyophilised powder was used as recovered or following coarse grinding. Structural integrity of dehydrated pDNA was assessed by agarose gel electrophoresis and powder particle size determined by laser diffraction. The apparent structure of the systems was visualised by scanning and transmission electron microscopy with the biological functionality quantified in vitro (A549 human lung epithelial cell line) by Green Fluorescent Protein (GFP) associated fluorescence. Lyophilisation produced large, irregularly shaped particles prior to (mean diameter ∼21 µm) and following (mean diameter ∼18 µm) coarse grinding. Spray-drying produced uniformly shaped spherical particles (mean diameter ∼4 µm). All dehydrated formulations mediated reporter gene expression in A549 cells with the spray-dried formulation generally proving superior even when compared with freshly prepared LPD complexes. Biological functionality of the LPD dry powders was not adversely affected following 3 months storage. Spray-drying has utility for producing stable, efficient and potentially respirable non-viral dry powder systems for respiratory gene delivery. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 32 references indexed in Scilit:
- Physical stability and in-vitro gene expression efficiency of nebulised lipid–peptide–DNA complexesInternational Journal of Pharmaceutics, 2000
- The Effect of Lyophilization on Plasmid DNA ActivityPharmaceutical Development and Technology, 2000
- Drug–surfactant–propellant interactions in HFA-formulationsInternational Journal of Pharmaceutics, 1999
- Activity–stability considerations of trypsinogen during spray drying: Effects of sucroseJournal of Pharmaceutical Sciences, 1999
- Solid State Characterization of Spray-Dried Powders of Recombinant Human Deoxyribonuclease (RhDNase)Journal of Pharmaceutical Sciences, 1998
- Aerosolization of Cationic Lipid:pDNA Complexes—In Vitro Optimization of Nebulizer Parameters for Human Clinical StudiesHuman Gene Therapy, 1998
- Stabilization of gene delivery systems by freeze-dryingInternational Journal of Pharmaceutics, 1997
- Protamine sulfate enhances lipid-mediated gene transferGene Therapy, 1997
- Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteersGene Therapy, 1997
- Gene therapy strategies for asthmaGene Therapy, 1997